Integrum appoints Martin Hillsten as new Chief Executive Officer
Integrum AB (INTEG) has appointed Martin Hillsten as its new CEO, effective immediately, replacing acting CEO Scott Flora. Hillsten, who previously served as CEO of Integration Diagnostics, brings 20 years of life sciences industry experience with expertise in implant products and diagnostic imaging. The company is implementing a strategic shift to accelerate market penetration of the OPRA® Implant System in the US and priority European markets.
The new strategy focuses on selected Centers of Excellence, strengthened aftermarket approach, and operational optimization expected to yield cost savings of up to SEK 20 million annually by early 2026. Flora will continue supporting US marketing activities in an advisory role while maintaining his position on the Board of Directors.
Integrum AB (INTEG) ha nominato Martin Hillsten come nuovo CEO, con effetto immediato, sostituendo l'amministratore delegato ad interim Scott Flora. Hillsten, che in precedenza è stato CEO di Integration Diagnostics, porta con sé 20 anni di esperienza nel settore delle scienze della vita, con competenze specifiche nei prodotti per impianti e nell'imaging diagnostico. L'azienda sta attuando un cambiamento strategico per accelerare la penetrazione sul mercato del OPRA® Implant System negli Stati Uniti e nei mercati europei prioritari.
La nuova strategia si concentra su Centri di Eccellenza selezionati, un approccio post-vendita rafforzato e un'ottimizzazione operativa che dovrebbe generare risparmi fino a 20 milioni di SEK all'anno entro l'inizio del 2026. Flora continuerà a supportare le attività di marketing negli Stati Uniti in un ruolo di consulenza, mantenendo al contempo la sua posizione nel Consiglio di Amministrazione.
Integrum AB (INTEG) ha nombrado a Martin Hillsten como su nuevo CEO, con efecto inmediato, reemplazando al CEO interino Scott Flora. Hillsten, que anteriormente fue CEO de Integration Diagnostics, aporta 20 años de experiencia en la industria de ciencias de la vida, con especialización en productos de implantes y imagen diagnóstica. La empresa está implementando un cambio estratégico para acelerar la penetración en el mercado del OPRA® Implant System en Estados Unidos y en los mercados europeos prioritarios.
La nueva estrategia se enfoca en Centros de Excelencia seleccionados, un enfoque fortalecido en el servicio postventa y una optimización operativa que se espera genere ahorros de hasta 20 millones de SEK anuales para principios de 2026. Flora continuará apoyando las actividades de marketing en EE. UU. en un rol asesor, manteniendo además su posición en la Junta Directiva.
Integrum AB (INTEG)는 Martin Hillsten을 새로운 CEO로 즉시 임명했으며, 임시 CEO인 Scott Flora를 대체합니다. 이전에 Integration Diagnostics의 CEO였던 Hillsten은 임플란트 제품과 진단 영상 분야의 전문성을 갖춘 생명과학 산업에서 20년의 경험을 보유하고 있습니다. 회사는 미국 및 우선 유럽 시장에서 OPRA® 임플란트 시스템의 시장 침투를 가속화하기 위한 전략적 전환을 시행하고 있습니다.
새 전략은 선정된 센터 오브 엑설런스에 집중하고, 강화된 애프터마켓 접근법과 운영 최적화를 통해 2026년 초까지 연간 최대 2,000만 SEK의 비용 절감을 기대하고 있습니다. Flora는 이사회 멤버 자리를 유지하면서 미국 마케팅 활동을 자문 역할로 계속 지원할 예정입니다.
Integrum AB (INTEG) a nommé Martin Hillsten comme nouveau PDG, avec effet immédiat, en remplacement du PDG par intérim Scott Flora. Hillsten, qui a précédemment été PDG d'Integration Diagnostics, apporte 20 ans d'expérience dans l'industrie des sciences de la vie, avec une expertise dans les produits d'implants et l'imagerie diagnostique. L'entreprise met en œuvre un changement stratégique pour accélérer la pénétration du marché du OPRA® Implant System aux États-Unis et sur les marchés européens prioritaires.
La nouvelle stratégie se concentre sur des Centres d'Excellence sélectionnés, une approche après-vente renforcée et une optimisation opérationnelle qui devrait permettre des économies allant jusqu'à 20 millions de SEK par an d'ici début 2026. Flora continuera de soutenir les activités marketing aux États-Unis en tant que conseiller tout en conservant son poste au conseil d'administration.
Integrum AB (INTEG) hat Martin Hillsten mit sofortiger Wirkung zum neuen CEO ernannt und ersetzt damit den amtierenden CEO Scott Flora. Hillsten, der zuvor CEO von Integration Diagnostics war, bringt 20 Jahre Erfahrung in der Life-Sciences-Branche mit, insbesondere in den Bereichen Implantatprodukte und diagnostische Bildgebung. Das Unternehmen setzt eine strategische Neuausrichtung um, um die Marktdurchdringung des OPRA® Implant Systems in den USA und den prioritären europäischen Märkten zu beschleunigen.
Die neue Strategie konzentriert sich auf ausgewählte Zentren der Exzellenz, einen verstärkten Aftermarket-Ansatz und operative Optimierungen, die bis Anfang 2026 Kosteneinsparungen von bis zu 20 Millionen SEK jährlich erwarten lassen. Flora wird weiterhin die Marketingaktivitäten in den USA in beratender Funktion unterstützen und gleichzeitig seine Position im Vorstand behalten.
- Strategic restructuring expected to generate significant cost savings of up to SEK 20 million annually by 2026
- New CEO brings extensive US market experience, with 70% of his previous company's revenues from US operations
- Optimization of operations and focus on Centers of Excellence could improve operating margins
- Implementation of cost-saving measures may cause short-term disruption
- Transition period with new leadership could temporarily impact operations
MÖLNDAL,
Integrum is implementing a strategic shift to accelerate market penetration of the OPRA® Implant System, concentrating on the US and prioritized European countries. The strategy includes a focus on selected Centers of Excellence, a strengthened aftermarket approach, and an optimization of operations that is expected to generate cost savings of up to
Martin Hillsten, born in 1978, holds a Bachelor of Business Administration from the University of
"Scott Flora, in his role as acting CEO, has established an efficient and well-functioning structure to accelerate the market penetration of the OPRA® Implant System. With the appointment of Martin Hillsten as new CEO, we ensure that Integrum can fully leverage the strategic shift initiated by the Board earlier this year Martin's extensive experience in sales and marketing of advanced medical devices, both in the US and abroad, along with his dedication to creating value for patients and shareholders, will constitute huge assets as we continue to establish Integrum as a world leader in bone-anchored implant systems," says Beng Sjöholm, Integrum's Chairman of the Board.
Scott Flora will continue to support the implementation of Integrum's marketing strategy in the US in an advisory role and will remain on the company's Board of Directors.
"I have followed Integrum's development for a long time and have been impressed by the company's revolutionary implant system. The strategic shift now being implemented, focusing on optimizing sales and marketing efforts, has good potential to create significant shareholder value by offering OPRA® Implant System to enhance the mobility of an increasing number of amputees. I am now taking over the baton to ensure sales growth while we continue implementing cost efficiencies that will contribute to significantly improved operating margins," comments Martin Hillsten, incoming CEO of Integrum.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-05-2025 14:59 CET.
For more information, please contact:
Bengt Sjöholm, Chairman of the Board
Tel: +46 70-531 38 11
Email: bengt.sjoholm@bsjab.se
Certified Adviser
Carnegie Investment Bank AB (publ) is the company's Certified Adviser.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Public/17531/4145152/bfd92e52796eb286.pdf | Integrum appoints new CEO ENG |
View original content:https://www.prnewswire.com/news-releases/integrum-appoints-martin-hillsten-as-new-chief-executive-officer-302446002.html
SOURCE Integrum AB
FAQ
Who is Martin Hillsten, the new CEO of Integrum (INTEG)?
What cost savings is Integrum (INTEG) expecting from its strategic shift?
What is Integrum's (INTEG) new strategic focus under Martin Hillsten?
What role will former acting CEO Scott Flora maintain at Integrum (INTEG)?
